Ablynx and Pfizer have extended their research collaboration and license agreement to discover and develop Nanobody-based therapeutics against tumor necrosis factor alpha (TNF-alpha), for another year. TNF-alpha is a key drug target in combating inflammation related disorders such as rheumatoid arthritis, Crohn’s disease, psoriatic arthritis and ankylosing spondylitis. Ablynx is eligible to receive royalties on product sales and Pfizer has exclusive rights to develop and commercialize a...